Virucidal pilot study of Nasodine® Antiseptic Nasal Spray (povidone-iodine 0.5%) in people with COVID-19 and confirmed nasal shedding of SARS-CoV-2 virus.

Phase 1

Withdrawn

• Conditions: COVID-19 Positive; Infection - Other infectious diseases; Respiratory - Other respiratory disorders / diseases

• Registration Number: ACTRN12620000470998
• Lead Sponsor: Firebrick Pharma Pty Ltd

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-04-14
• Last Update Posted: 18 October 2021

Recruitment & Eligibility

• Status: Withdrawn
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Adult (18+ years old) patients with
(a) confirmed COVID-19 symptoms and
(b) symptom onset within the past five days.

Exclusion Criteria

•Known iodine sensitivity
•Previously diagnosed thyroid disease
•Previously diagnosed kidney disease
•Known to be pregnant or currently breastfeeding

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Impact of Nasodine on the reduction in virus in the nasal passages of subjects who are shedding the virus. Virus concentration is measured by PCR analysis of cell culture medium 96 hours after inoculation with a post-treatment nasal swab and compared to an equivalent culture inoculated with swab collected prior to treatment.[Endpoint is swab taken 5 minutes after dosing and compared against a swab taken 5 minutes prior to dosing.]

Secondary Outcome Measures

Name	Time	Method
Impact of Nasodine on the reduction in virus in the nasal passages of subjects who are shedding the virus. Virus concentration is measured by PCR analysis of cell culture medium 96 hours after inoculation with a post-treatment nasal swab and compared to an equivalent culture inoculated with swab collected prior to treatment.[Endpoint is swab taken 1 hour after dosing and compared against a swab taken 5 minutes prior to dosing.]